Ligand Pharmaceuticals Cash Flow Statement (2010-2025) | LGND

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Operating Activities
Net Income (Quarter)	-4.66M	-5.72M	-6.62M	-2.22M	-2.46M	-13.49M	-9.24M	-2.95M	-1.67M							-31.09M	-42.45M	4.85M	117.27M	44.78M
Depreciation and Depletion (Quarter)													0.58M	0.60M	0.74M	0.39M	0.51M	0.26M	0.17M	0.05M
Share-based Compensation (Quarter)	8.40M	10.22M	9.75M	10.41M	9.04M	9.50M	12.60M	29.14M	5.93M	7.21M	6.88M	5.72M	7.33M	11.06M	15.17M	7.52M	7.84M	10.00M	14.75M	14.27M
Deferred Taxes (Quarter)	12.41M	-2.64M	-1.54M	0.39M	16.18M	-3.25M	12.64M	-46.29M	-8.75M	10.00M	-8.01M	-4.93M	-19.55M	20.67M	1.99M	12.69M	8.84M	0.33M	-21.28M	-10.57M
Cash from Discontinued Operations (Quarter)
Gains from Sales and Divestitures (Quarter)
Gains from Investment Securities (Quarter)		-0.14M	0.14M	6.02M	0.75M	5.17M	-6.00M	1.04M	4.16M	0.03M	11.05M	-15.19M	3.08M	-2.08M		0.77M	0.80M	1.51M	-2.29M	0.01M
Asset Writedowns and Impairment (Quarter)
Non-cash Items (Quarter)
Cash from Operations (Quarter)	10.75M	20.38M	20.02M	27.64M	52.01M	11.88M	20.49M	53.47M	33.95M	-0.08M	7.65M	8.06M	18.73M	13.31M	36.53M	28.47M	-25.45M	15.80M	13.09M	45.91M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)	-0.15M	0.04M	-0.04M	0.03M	-0.05M	0.01M	-0.03M	0.06M	0.28M	0.38M	0.28M	0.38M	0.16M	0.43M	0.14M	0.61M	0.84M	0.77M	1.34M	2.02M
Amortization of Deferred Charges (Quarter)	4.92M	4.16M	3.79M	3.83M	0.33M	0.20M	0.10M	0.10M	0.10M	0.10M		0.08M	0.08M	0.10M	0.13M	0.17M	0.14M	0.12M	0.40M	0.56M
Depreciation & Amortization (CF) (Quarter)	12.56M	12.61M	12.72M	13.17M	13.65M	13.27M	13.48M	11.13M	9.50M	9.49M	8.61M	8.92M	8.77M	8.85M	8.99M	8.63M	8.77M	8.52M	8.27M	8.21M
Change in Working Capital
Change in Receivables (Quarter)	-2.41M	5.07M	6.18M	19.78M	-43.64M	20.43M	2.66M	-34.77M	-1.10M	-1.38M	7.91M	-2.83M	-3.46M	9.05M	-4.79M	5.67M	0.58M	2.77M	16.31M	2.09M
Change in Inventory (Quarter)	9.67M	-7.34M	0.78M	-2.68M	-0.04M	-9.70M	-0.96M	-1.36M	-2.04M	13.00M	0.61M	-0.71M	-2.63M	-2.49M	-1.93M	-2.57M	0.50M	0.88M	-3.59M	-2.77M
Change in Accured Expenses (Quarter)	0.47M	-4.81M	0.70M	6.45M	-2.71M	-1.65M	3.95M	-2.94M	-0.43M	-4.53M	-2.50M	2.76M	-1.38M	1.77M	2.23M	11.29M	-2.15M	-0.41M	1.09M	7.34M
Change in Taxes (Quarter)	1.07M	-3.55M	-1.69M	8.14M	11.99M	-2.98M	6.10M	-16.69M	-4.61M	-11.39M	10.18M	7.60M	-7.53M	-0.95M	9.09M	-2.92M	-0.34M	-2.42M	-0.86M	0.95M
Other Working Capital Changes (Quarter)	-5.70M	-8.91M	15.26M	0.91M	-0.08M	3.59M	-8.69M	5.55M	-0.68M	0.83M	0.06M	0.52M	3.46M	-4.40M	1.06M	-1.41M	0.92M	0.82M	-2.31M	2.27M
Investing Activities
Capital Expenditures (Quarter)	3.40M	-3.04M	0.20M	8.20M	4.88M	6.59M	4.33M	2.13M	2.41M	-1.88M	-0.12M	-0.41M	0.10M	0.41M	74.49M	-73.18M	0.21M	0.21M	-0.43M	0.45M
Sales of Property, Plant and Equipment (Quarter)
Change in Intangibles (Quarter)
Acquisitions (Quarter)																-92.00M
Change in Acquisitions & Divestments (Quarter)	109.41M	-74.81M	117.86M	-85.36M	24.83M		177.72M	7.01M	8.46M	80.37M	7.49M	-50.92M	14.54M	9.07M	165.95M	-156.43M	38.41M	44.81M	-44.62M	120.98M
Cash from Investing Activities (Quarter)	65.11M	19.34M	-18.22M	-35.71M	113.88M	37.85M	19.18M	-7.28M	10.55M	7.56M	-19.50M	-10.28M	-3.77M	-54.76M	-46.51M	-38.62M	4.89M	-10.67M	-353.44M	-18.10M
Financing Activities
Other financing activities (Quarter)					-0.12M	0.09M	-0.01M	0.04M				0.95M	0.04M	0.06M	0.21M	0.12M	0.07M	0.00M	14.84M	0.62M
Cash from Financing Activities (Quarter)	-91.64M	-49.91M	-0.39M	4.16M	-170.42M	-59.44M	-40.83M	-5.30M	-0.78M	-67.76M	3.27M	5.32M	12.18M	9.49M	55.08M	20.39M	-4.75M	14.99M	409.64M	8.33M
Additional items
Exchange Rate Effect (Quarter)														-4.82M	5.19M	-1.55M	1.06M	2.29M	-0.40M	-0.59M
Change in Cash (Quarter)	-15.77M	-10.19M	1.42M	-3.91M	-4.53M	-9.71M	-1.16M	40.89M	43.72M	-60.28M	-8.59M	3.10M			40.66M	8.69M	-24.32M	21.50M	69.89M	35.55M
Free Cash Flow (Quarter)	7.35M	23.42M	19.83M	19.44M	47.14M	5.29M	16.16M	51.34M	31.53M	1.80M	7.77M	8.47M	18.63M	12.91M	-37.96M	101.65M	-25.66M	15.59M	13.52M	45.46M
Net Cash Flow (Quarter)	-15.77M	-10.19M	1.42M	-3.91M	-4.53M	-9.71M	-1.16M	40.89M	43.72M	-60.28M	-8.59M	3.10M	27.14M	-31.95M	45.10M	10.24M	-25.30M	20.13M	69.29M	36.14M

Research Tools

Ligand Pharmaceuticals Cash Flow Statement (2010-2025) | LGND

Create an account

Sign In

Reset Password